FDA Approves New Treatment for HoFH

No Comments

On Dec 24th, 2012 Aegerion Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) approved new treatment for Homozygous Familial Hypercholesterolemia (HoFH) called JUXTAPID™ (lomitapide). The capsules are intended as an adjunct to a low-fat diet and other cholesterol-lowering … Read More

Learn About Cascade Screening and FH


In September, the FH Foundation participated in the “New Strategies in Public Health Genomics” conference at the Centers for Disease Control (CDC).  Experts and key stakeholders, including advocates, community leaders and clinicians, came together to discuss evidence-based genomic programs … Read More

Public FDA hearing on October 17th and 18th

No Comments

FDA Advisory Committee Information:

Notices of the upcoming Endocrinologic and Metabolic Drugs Advisory Committee meetings have been made available on the FDA website: https://www.fda.gov/advisorycommittees/default.htm

Date and Time: The meetings will be held on October 17 and 18, 2012, from 8 a.m. … Read More

Call for screening to detect

No Comments

TENS of thousands of patients who have inherited a dangerously high risk of a heart attack in early life are going undetected, warn cardiologists, who are calling for a new integrated screening system to pick up their condition before it becomes life-threatening.


The condition, called familial … Read More

1 40 41 42